Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation.-论文-万方医学网

第一作者： Elena,Díaz-García

第一单位： Respiratory Diseases Group, Respiratory Service, La Paz University Hospital, Instituto de Investigación Biomédica del Hospital Universitario la Paz (IdiPAZ), Madrid, Spain.;Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain.

作者： Elena,Díaz-García ^[1] ; Sara,García-Tovar ^[2] ; Enrique,Alfaro ^[2] ; Ester,Zamarrón ^[1] ; Alberto,Mangas ^[2] ; Raúl,Galera ^[1] ; José Juan,Ruíz-Hernández ^[3] ; Jordi,Solé-Violán ^[4] ; Carlos,Rodríguez-Gallego ^[5] ; Ana,Van-Den-Rym ^[6] ; Rebeca,Pérez-de-Diego ^[6] ; Kapil,Nanwani-Nanwani ^[7] ; Eduardo,López-Collazo ^[8] ; Francisco,García-Rio ^[9] ; Carolina,Cubillos-Zapata ^[1]

作者单位： Respiratory Diseases Group, Respiratory Service, La Paz University Hospital, Instituto de Investigación Biomédica del Hospital Universitario la Paz (IdiPAZ), Madrid, Spain.;Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain. ^[1] Respiratory Diseases Group, Respiratory Service, La Paz University Hospital, Instituto de Investigación Biomédica del Hospital Universitario la Paz (IdiPAZ), Madrid, Spain. ^[2] Department of Internal Medicine, Gran Canaria Dr Negrín University Hospital, Gran Canaria, Spain. ^[3] Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain.;Intensitive Care Medicine, Gran Canaria Dr Negrín University Hospital, Gran Canaria, Spain. ^[4] Departament of Immunology, Gran Canaria Dr Negrín University Hospital, Gran Canaria, Spain.;Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain. ^[5] Laboratory of Immunogenetics of Human Diseases, La Paz University Hospital, Instituto de Investigación Biomédica del Hospital Universitario la Paz (IdiPAZ), Madrid, Spain.;Interdepartmental Group of Immunodeficiencies, Madrid, Spain. ^[6] Department of Intensive Medicine, La Paz University Hospital, Madrid, Spain. ^[7] The Innate Immune Response Group, La Paz University Hospital, Instituto de Investigación Biomédica del Hospital Universitario la Paz (IdiPAZ), Madrid, Spain. ^[8] Respiratory Diseases Group, Respiratory Service, La Paz University Hospital, Instituto de Investigación Biomédica del Hospital Universitario la Paz (IdiPAZ), Madrid, Spain.;Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain.;Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain. ^[9]

医学主题词腺苷二磷酸(Adenosine Diphosphate);腺苷三磷酸(Adenosine Triphosphate);腺苷三磷酸双磷酸酶(Apyrase);血小板(Blood Platelets);细胞低氧(Cell Hypoxia);危重病人医疗(Critical Care);女(雌)性(Female);人类(Humans);流感病毒A型(Influenza A virus);流感, 人(Influenza, Human);住院时间(Length of Stay);男(雄)性(Male);中年人(Middle Aged);血小板活化(Platelet Activation);预后(Prognosis);前瞻性研究(Prospective Studies);嘌呤能P2Y受体拮抗剂(Purinergic P2Y Receptor Antagonists);受体, 嘌呤能P2Y(Receptors, Purinergic P2Y);疾病严重程度指数(Severity of Illness Index);信号传导(Signal Transduction)

DOI 10.3389/fimmu.2022.847894

PMID 35173744

发布时间 2022-03-02

检索历史清除

Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation.

Frontiers in immunology

相似文献

同项目论文

Frontiers in immunology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation.

Frontiers in immunology

相似文献

同项目论文

Frontiers in immunology

相关期刊

检索历史清除